

ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX)
SCHEDULE OF INVESTMENTS (Unaudited)
December 31, 2021

Shares		Fair Value
	COMMON STOCKS — 98.1%	
	BIOTECH & PHARMA - 91.9%	
10,000	2seventy bio, Inc. ^(a)	\$ 256,300
51,500	ACADIA Pharmaceuticals, Inc. ^(a)	1,202,010
68,000	Aclaris Therapeutics, Inc. ^(a)	988,720
137,000	Aerie Pharmaceuticals, Inc. ^(a)	961,740
11,500	Agios Pharmaceuticals, Inc. ^(a)	378,005
24,500	ALX Oncology Holdings, Inc. ^(a)	526,505
150,000	Amarin Corp plc - ADR ^(a)	505,500
52,500	Arcutis Biotherapeutics, Inc. ^(a)	1,088,850
16,500	Arena Pharmaceuticals, Inc. ^(a)	1,533,510
20,538	Athira Pharma, Inc. ^(a)	267,610
17,500	BioCryst Pharmaceuticals, Inc. ^(a)	242,375
9,500	BioMarin Pharmaceutical, Inc. ^(a)	839,325
12,000	Bristol-Myers Squibb Company	748,200
16,000	Caribou Biosciences, Inc. ^(a)	241,440
17,000	Celldex Therapeutics, Inc. ^(a)	656,880
37,500	Cogent Biosciences, Inc. ^(a)	321,750
60,500	Collegium Pharmaceutical, Inc. ^(a)	1,130,140
17,500	Compass Pathways plc - ADR ^(a)	386,750
38,000	Exelixis, Inc. ^(a)	694,640
28,500	Fulcrum Therapeutics, Inc. ^(a)	504,165
100,000	Fusion Pharmaceuticals, Inc. ^(a)	417,000
31,000	Galapagos N.V. - ADR ^(a)	1,709,030
61,500	Genetron Holdings Ltd. - ADR ^(a)	375,150
1,000	Horizon Therapeutics plc ^(a)	107,760
20,000	Incyte Corporation ^(a)	1,468,000
28,500	Insmed, Inc. ^(a)	776,340
20,000	Iovance Biotherapeutics, Inc. ^(a)	381,800
15,000	iTeos Therapeutics, Inc. ^(a)	698,400
10,000	Jazz Pharmaceuticals plc ^(a)	1,274,000
140,000	Karyopharm Therapeutics, Inc. ^(a)	900,200
3,000	Legend Biotech Corporation - ADR ^(a)	139,830
8,000	Merck & Company, Inc.	613,120
5,500	Morphic Holding, Inc. ^(a)	260,590
145,500	MorphoSys A.G. - ADR ^(a)	1,370,610

ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX)
SCHEDULE OF INVESTMENTS (Unaudited) (Continued)
December 31, 2021

Shares		Fair Value
	COMMON STOCKS — 98.1% (Continued)	
	BIOTECH & PHARMA - 91.9% (Continued)	
17,500	PTC Therapeutics, Inc. ^(a)	\$ 697,025
400,000	Puma Biotechnology, Inc. ^(a)	1,216,000
65,000	Revance Therapeutics, Inc. ^(a)	1,060,800
11,000	Sage Therapeutics, Inc. ^(a)	467,940
6,000	Sanofi - ADR	300,600
6,000	Sarepta Therapeutics, Inc. ^(a)	540,300
50,000	Takeda Pharmaceutical Company Ltd. - ADR	681,500
151,000	TCR2 Therapeutics, Inc. ^(a)	703,660
17,000	Turning Point Therapeutics, Inc. ^(a)	810,900
1,100	United Therapeutics Corporation ^(a)	237,688
90,000	Viracta Therapeutics, Inc. ^(a)	328,500
82,500	Zogenix, Inc. ^(a)	1,340,625
		<u>32,351,783</u>
	HEALTH CARE FACILITIES & SERVICES - 2.2%	
31,500	AdaptHealth Corporation ^(a)	770,490
	MEDICAL EQUIPMENT & DEVICES - 1.8%	
9,500	Castle Biosciences, Inc. ^(a)	407,265
23,000	Zynex, Inc.	229,310
		<u>636,575</u>
	TOBACCO & CANNABIS - 2.2%	
265,000	Columbia Care, Inc. ^(a)	758,033
		<u>758,033</u>
	TOTAL COMMON STOCKS (Cost \$37,661,343)	<u>34,516,881</u>
	SHORT-TERM INVESTMENT — 0.0%^(b)	
	MONEY MARKET FUND - 0.0%^(b)	
1	Fidelity Government Portfolio, CLASS I, 0.01% (Cost \$1) ^(c)	1
		<u>1</u>
	TOTAL INVESTMENTS - 98.1% (Cost \$37,661,344)	\$ 34,516,882
	OTHER ASSETS IN EXCESS OF LIABILITIES - 1.9%	<u>681,991</u>
	NET ASSETS - 100.0%	<u>\$ 35,198,873</u>

ADR - American Depositary Receipt
LTD - Limited Company
NV - Naamioze Vennootschap
PLC - Public Limited Company

- (a) Non-income producing security.
- (b) Percentage rounds to less than 0.1%.
- (c) Rate disclosed is the seven day effective yield as of December 31, 2021.